Glenmark Pharmaceuticals Ltd News

Stocks to Watch today: Acme Solar, Indian Oil, Power Grid, Glenmark Pharma

Stocks to Watch today, April 2, 2026: Lupin, Inox Clean Energy, Latent View Analytics, Jubilant FoodWorks, and Lemon Tree Hotels are among the top stocks to watch during today's trading session

Glenmark takes direct control of Ryaltris sales in US from April 2026

Glenmark will directly manage Ryaltris sales in the US from April 2026, strengthening its innovation-led portfolio and expanding its commercial presence in the market

Astral, Glenmark, Nalco among high conviction F&O bets in April: Systematix

The futures & options market positioning reflects heavy short build-up, creating conditions for sharp but temporary short-covering rallies, says Systematix Institutional Equities.

Analyst suggests Nifty strategy; bets on BSE, Delhivery, Glenmark Pharma

Ajit Mishra of Religare Broking recommends buying the shares of BSE, Delhivery, and Glenmark Pharmaceuticals today; check all the key details here

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Glenmark to launch generic sodium phosphates injection in US in April 2026

Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.

Further downside ahead for Nifty? Here's today's outlook and top picks

Ajit Mishra of Religare Broking recommended Glenmark Pharmaceuticals, TVS Motor Company, and Power Finance Corporation for Thursday's session

Voda Idea, DLF, RBL Bank among 18 F&O stocks to attract 15% higher margin

The NSE to levy 15% additional margin on equity derivatives in which top 10 clients account for more than 20% MWPL from March F&O series onwards; withdraws additional margin on Gold, Silver futures.

Nifty outlook: Index to consolidate; Ajit Mishra suggests 3 stocks to buy

Nifty outlook for Feb 12: Index consolidates near 25,950 amid mixed sectoral trends. Ajit Mishra recommends Glenmark Pharma, Nippon Life and TVS Motor as stocks to buy today.

Stocks to Watch today, Feb 1: Defence, Infra, Meesho, Ola, Sun Pharma

Stocks to Watch today, February 1, 2026: From Glenmark Pharma to Ola Electric, here are few shares that will remain in focus

Glenmark Q3 profit rises 15% on strong market performance; Revenue up 15%

Pharma major reports double-digit growth in Q3 as India and North America lead performance, though profit and revenue declined sequentially

Pharma index hits 52-week high; Glenmark, Lupin rally 3% in subdued market

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Stocks to Watch today, Dec 17: Ola Electric, Vedanta, HDFC Bank, Akzo Nobel

Stocks to Watch today, December 17, 2025: From Ola Electric to Vedanta, here is a list of stocks that will be on traders' and investors' radar

Glenmark Pharma rises 2% on positive US FDA inspection report; details here

The company informed exchanges that it has received the EIR from the US FDA for its formulations manufacturing facility in Monroe, North Carolina, with a Voluntary Action Indicated (VAI) status

Trading guide: Nifty eyes 26,500; Axis Bank, Glenmark on analyst radar

Stocks to buy: Ajit Mishra of Religare Broking recommends buying Axis Bank, Glenmark Pharma, and United Spirits; also suggests Nifty trading strategy

Glenmark Pharma stock gains 3% on launch novel COPD treatment; details here

The company has launched Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, world's first nebulised, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

Glenmark Pharma shares rise after 72% Q2 profit jump; check outlook here

Glenmark Pharma shares rose after the company reported a 72.2 per cent surge in profit after tax to ₹610.43 crore in September quarter

Stocks to Watch today, Nov 17: Maruti Suzuki, Ola Electric, Marico, Lupin

Stocks to Watch Today, November 17, 2025: Marico, Glenmark Pharma, FirstCry, Siemens, Dish TV, Alembic Pharma, Cyient, and Websol Energy System are among the top stocks to remain in focus today

Glenmark Pharmaceuticals Q2 results: Profit jumps 72% to ₹610.43 cr

Glenmark Pharmaceuticals Ltd on Friday reported a 72.2 per cent jump in consolidated profit after tax at Rs 610.43 crore in the second quarter ended September 2025 on the back of its licensing deal with AbbVie for investigational asset 'ISB 2001'. The company had posted a consolidated profit after tax (PAT) of Rs 354.49 crore in the corresponding period last fiscal, Glenmark Pharmaceuticals Ltd said in a regulatory filing. Consolidated total revenue from operations was at Rs 6,046.87 crore as against Rs 3,433.8 crore in the same period a year ago, it added. Total expenses in the quarter under review were at Rs 3,894.98 crore as against Rs 3,000.64 crore in the same period last fiscal, the company said. "Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the